Clinical trials
Completed Phase 1/2 trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
466 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 5 |
| 2011 | 13 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 20 |
| 2015 | 30 |
| 2016 | 43 |
| 2017 | 30 |
| 2018 | 29 |
| 2019 | 31 |
| 2020 | 49 |
| 2021 | 53 |
| 2022 | 48 |
| 2023 | 37 |
| 2024 | 23 |
| 2025 | 7 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 466 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fuda Cancer Hospital, Guangzhou | 54 |
| Akeso | 15 |
| Sun Yat-sen University | 10 |
| Jiangsu HengRui Medicine Co., Ltd. | 9 |
| Capital Medical University | 8 |
| Shanghai Junshi Bioscience Co., Ltd. | 8 |
| BeiGene | 6 |
| Chinese PLA General Hospital | 6 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 6 |
| Bristol-Myers Squibb | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 18 |
| Breast Neoplasms | 15 |
| Colorectal Neoplasms | 15 |
| Lung Neoplasms | 15 |
| COVID-19 | 13 |
| Carcinoma, Hepatocellular | 13 |
| Liver Neoplasms | 13 |
| Neoplasms | 13 |
| Pancreatic Neoplasms | 11 |
| Diabetes Mellitus, Type 2 | 9 |
Trials
Showing 1 to 25 of 466. Each trial links to its page on Pharma Observatory.
366 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.